Trial Profile

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Kamuvudine 9 (Primary)
Indications Graves ophthalmopathy
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

08 Aug 2025 Protocol has been amended , dosing duration is changed from 4 weeks to 24 weeks.
08 Aug 2025 Planned number of patients changed from 8 to 13.
08 Aug 2025 Planned End Date changed from 1 May 2025 to 1 Aug 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com